Latest Deals
The transaction will see OrganOx become a wholly owned subsidiary of Terumo. Credit: JHVEPhoto / Shutterstock.com
Terumo signs agreement to buy OrganOx for $1.5bn
Terumo has signed a definitive agreement to acquire OrganOx, a provider of organ preservation devices, in a deal valued at $1.5bn. OrganOx will become a wholly owned subsidiary of Terumo, which had already invested through its venture capital arm in March. By combining Terumo’s medical device expertise with OrganOx’s normothermic machine perfusion (NMP) technology, the company aims to expand access to organ preservation devices worldwide.
ViCentra raises $85m to drive insulin pump’s US market entry
Dutch device company ViCentra has raised $85m to boost its Kaleido insulin patch pump’s entry onto the US market. The latest funding will also support the scale-up of ViCentra’s manufacturing capabilities to meet this demand, along with filing activities with the US Food and Drug Administration (FDA) to support Kaleido’s US market entry.
Cyted raises $44m to propel US market expansion of its endoscopic capsule
UK-based Cyted Health has raised $44m to accelerate the ongoing market adoption of its EndoSign device in the US. Cyted’s CEO Marcel Gehrung said the investment will help consolidate its position in the US market by expanding its presence and adding further innovations to its diagnostics portfolio.
Ketryx raises $39m to advance AI compliance platform
Ketryx has raised $39m to support the ongoing development of its AI-powered compliance platform. Transformation Capital led the Series B funding round, which brings Ketryx’s funding to date to more than $55m. Other participants included existing investors such as Lightspeed Venture Partners, Ubiquity Ventures, and 53 Stations.
